Clinical Inquiries

How effective and safe is fecal microbial transplant in preventing C difficile recurrence?

Author and Disclosure Information

 

References

Fresh and frozen stool are equally effective

A randomized, double-blind noninferiority trial compared the effectiveness of frozen and thawed FMT with that of fresh FMT in 219 patients ≥18 years of age with recurrent or refractory CDIs.3 Researchers prescribed suppressive antibiotics, which were discontinued within 24 to 48 hours of FMT, and then administered 50 mL of either fresh or frozen stool by enema. They repeated the FMT with the same donor stool if symptoms didn’t improve within 4 days. Any patient still unresponsive was offered repeat FMT or antibiotic therapy.

Researchers defined a 15% difference in outcome as a clinically important effect. Intention-to-treat analysis yielded no significant difference in clinical resolution between groups (75% frozen vs 70.3% fresh; P=.01 for noninferiority).

Nasogastric delivery works as well as colonoscopy

An open-label RCT (not included in the reviews described previously) evaluated the effectiveness of colonoscopically administered FMT compared with that of nasogastric administration in 20 patients with recurrent or refractory CDIs.4 Patients had experienced either a minimum of 3 episodes of mild-to-moderate CDI with a failed 6- to 8-week taper of vancomycin or 2 episodes of severe CDI resulting in hospitalization. Researchers offered patients from both groups a second FMT if symptoms didn’t improve with the initial administration.

Eight patients in the colonoscopy group and 6 in the nasogastric group were cured (all symptoms resolved) after the first FMT. One patient in the nasogastric group refused subsequent administration. All 5 remaining participants chose to have subsequent nasogastric administration (80% cure rate). Both methods of administering FMT produced comparable cure rates (80% in the initial nasogastric group vs 100% in the initial colonoscopy group; P=.53).

Continue to: A third of patients suffer adverse effects, but serious harms are rare

Evidence-based answers from the Family Physicians Inquiries Network

Recommended Reading

Breath test may detect esophagogastric cancer
MDedge Family Medicine
How to choose between highly effective HBV therapies
MDedge Family Medicine
VIDEO: Characteristic flora define intestinal microbiome in scleroderma
MDedge Family Medicine
Blood type A linked to more-severe diarrhea
MDedge Family Medicine
IBD upped Parkinson’s risk in large study
MDedge Family Medicine
FDA approves Doptelet for liver disease patients undergoing procedures
MDedge Family Medicine
Recent studies of microbiota offer insights into digestive disease management
MDedge Family Medicine
Experimental drug may help those living with celiac disease
MDedge Family Medicine
MDedge Daily News: Keeping patients summer safe
MDedge Family Medicine
FDA expands Xeljanz approval to certain adults with ulcerative colitis
MDedge Family Medicine